AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

On April25, 2017, AveXis,Inc. (the Company) will
host a live webcast to report on results from the closeout of the
Companys Phase 1 clinical trial of AVXS-101 for the treatment of
spinal muscular atrophy (SMA) Type 1.
These data were presented by Jerry Mendell, M.D., principal
investigator in the trial and Curran-Peters Chair of Pediatric
Research, Professor of Pediatrics and Neurology at the Research
Institute at Nationwide Childrens Hospital and The Ohio State
University, during the Clinical Trial Plenary Session at the 2017
Annual Meeting of the American Academy of Neurology in Boston,
Massachusetts. A copy of the slides to be presented during the
webcast is being furnished as Exhibit99.1 to this Current Report
on Form8-K.

The information in this Item 7.01 of this Current Report on
Form8-K (including Exhibit99.1) is being furnished and shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On April25, 2017, the Company issued a press release reporting on
the results from the closeout of the Companys Phase 1 clinical
trial of AVXS-101 for the treatment of SMA Type 1 as presented by
Dr.Mendell at the 2017 Annual Meeting of the American Academy of
Neurology. The full text of the Companys press release regarding
the announcement is filed as Exhibit99.2 to this Current Report
on Form8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and
Exhibits.

(d)Exhibits

About AVEXIS, INC. (NASDAQ:AVXS)

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

AVEXIS, INC. (NASDAQ:AVXS) Recent Trading Information

AVEXIS, INC. (NASDAQ:AVXS) closed its last trading session up +2.92 at 82.10 with 382,282 shares trading hands.